Publication Author: Devine_Emily
-
Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance.
Johnson KM, Jiao B, Ramsey SD, Bender MA, Devine B, Basu A. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. Blood Adv. 2022 May 16. pii: bloodadvances.2021006281. doi: 10.1182/bloodadvance
rakerr2
-
Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease.
Johnson KM, Jiao B, Bender MA, Ramsey SD, Devine B, Basu A. Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease. PLoS One. 2022 Apr 28;17(4):e0267448. doi: 10.1371/journal.pone.0267448. eCollect
rakerr2
-
Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis.
Baldwin Z, Jiao B, Basu A, Roth J, Bender MA, Elsisi Z, Johnson KM, Cousin E, Ramsey SD, Devine B. Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis. Pharmacoecon Open. 20
rakerr2
-
A landscape analysis and discussion of value of gene therapies for sickle cell disease.
Quach D, Jiao B, Basu A, Bender MA, Hankins J, Ramsey S, Devine B. A landscape analysis and discussion of value of gene therapies for sickle cell disease. Expert Rev Pharmacoecon Outcomes Res. 2022 Apr 18:1-21. doi: 10.1080/14737167.2022.2060823. [Epub ah
rakerr2
-
Prevalence and prediction of medical distrust in a diverse medical genomic research sample.
Angelo F, Veenstra D, Knerr S, Devine B. Prevalence and prediction of medical distrust in a diverse medical genomic research sample. Genet Med. 2022 Apr 6. pii: S1098-3600(22)00697-9. doi: 10.1016/j.gim.2022.03.007. [Epub ahead of print]
rakerr2
-
Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review.
Jiao B, Basu A, Ramsey S, Roth J, Bender MA, Quach D, Devine B. Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review. Value Health. 2022 Feb;25(2):276-287. doi: 10.1016/j.jval.2021.08.002. Epub 2021 Sep 4.
rakerr2
-
Exploring Providers’ Perception to Naloxone Education for Opioid Overdose After Receiving Academic Detailing at the U.S. Department of Veterans Affairs.
Bounthavong M, Christopher MLD, Veenstra DL, Basu A, Devine EB. Exploring Providers’ Perception to Naloxone Education for Opioid Overdose After Receiving Academic Detailing at the U.S. Department of Veterans Affairs. J Pharm Pract. 2021 Nov 12:89719002110
rakerr2
-
Meta-analyzing count events over varying durations using the piecewise Poisson model: The case for poststroke seizures.
Wang WJ, Devine B, Bansal A, White HS, Basu A. Meta-analyzing count events over varying durations using the piecewise Poisson model: The case for poststroke seizures. Res Synth Methods. 2020 Nov 1. doi: 10.1002/jrsm.1465. [Epub ahead of print]
rakerr2
-
Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.
Chen S, Graff J, Yun S, Beal B, Ta JT, Bansal A, Carlson JJ, Veenstra DL, Basu A, Devine B. Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making. J Manag Care Spec Pharm. 2021 Jan;27(1):
rakerr2
-
Providers’ perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment.
Bounthavong M, Suh K, Christopher MLD, Veenstra DL, Basu A, Devine EB. Providers’ perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qu
rakerr2